We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+15.32%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.02B
AUM Growth
+$175M
(+3.6%)
Cap. Flow
-$2.02B
Cap. Flow
% of AUM
-40.15%
Top 10 Holdings %
Top 10 Hldgs %
37.55%
Holding
141
New
17
Increased
15
Reduced
22
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$70.1M |
| 2 |
CPRX
Catalyst Pharmaceutical
CPRX
|
+$58M |
| 3 |
Revolution Medicines
RVMD
|
+$44M |
| 4 |
Larimar Therapeutics
LRMR
|
+$27.8M |
| 5 |
VERV
Verve Therapeutics
VERV
|
+$23.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viatris
VTRS
|
+$98.4M |
| 2 |
AdaptHealth
AHCO
|
+$60.2M |
| 3 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$59M |
| 4 |
Glaukos
GKOS
|
+$53.6M |
| 5 |
DAWN
Day One Biopharmaceuticals
DAWN
|
+$52.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 53.48% |
| 2 | Financials | 1.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Centene
CNC
$32.9B
| $36.1M | 0.72% |
464,000
-114,800
| -20% | -$10.3M |
|
|
AMED
27
DELISTED
Amedisys
AMED
| $34.8M | 0.69% |
359,765
+160,765
| +81% | +$19.2M |
|
28
Phreesia
PHR
$648M
| $34.6M | 0.69% |
1,358,000
+500,885
| +58% | +$12.5M |
|
|
BLU
29
DELISTED
BELLUS Health Inc.
BLU
| $32.5M | 0.65% |
3,081,000
+608,000
| +25% | +$6.46M |
|
30
Kura Oncology
KURA
$968M
| $30.3M | 0.6% |
2,219,128
-407,872
| -16% | -$6.29M |
|
31
Phathom Pharmaceuticals
PHAT
$861M
| $26.8M | 0.53% |
+2,414,897
| New | +$23M |
|
32
IDEAYA Biosciences
IDYA
$3.48B
| $26M | 0.52% |
+1,743,628
| New | +$22.6M |
|
|
VERV
33
DELISTED
Verve Therapeutics
VERV
| $25.8M | 0.51% |
+750,000
| New | +$23.9M |
|
34
Molina Healthcare
MOH
$11.8B
| $24.7M | 0.49% |
75,000
-92,000
| -55% | -$29.6M |
|
|
SWTX
35
DELISTED
SpringWorks Therapeutics
SWTX
| $23.3M | 0.46% |
+816,994
| New | +$23.4M |
|
36
Tarsus Pharmaceuticals
TARS
$2.57B
| $22.7M | 0.45% |
1,324,214
| – | – |
|
37
Alphatec Holdings
ATEC
$1.29B
| $22.1M | 0.44% |
2,532,792
+112,245
| +5% | +$888K |
|
38
Insmed
INSM
$23.4B
| $20.7M | 0.41% |
960,484
| – | – |
|
|
DAWN
39
DELISTED
Day One Biopharmaceuticals
DAWN
| $20.7M | 0.41% |
1,032,000
-2,480,123
| -71% | -$52.7M |
|
|
EHAB
40
DELISTED
Enhabit
EHAB
| $20.4M | 0.41% |
+1,454,279
| New | +$23.6M |
|
|
VIGL
41
DELISTED
Vigil Neuroscience
VIGL
| $18M | 0.36% |
+2,054,794
| New | +$15.1M |
|
|
ISEE
42
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $17.9M | 0.36% |
+1,000,000
| New | +$13.1M |
|
|
OMIC
43
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| $17.7M | 0.35% |
235,934
+24,723
| +12% | +$2.58M |
|
44
TG Therapeutics
TGTX
$8.42B
| $15.9M | 0.32% |
2,677,500
| – | – |
|
|
DALS
45
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
| $15.6M | 0.31% |
1,600,000
| – | – |
|
46
The Oncology Institute
TOI
$543M
| $15.6M | 0.31% |
3,360,052
-23,047
| -0.7% | -$136K |
|
47
Pacira BioSciences
PCRX
$1.02B
| $15.5M | 0.31% |
292,000
| – | – |
|
48
GeneDx Holdings
WGS
$1.84B
| $14.9M | 0.3% |
514,348
-56,818
| -10% | -$2.6M |
|
49
Rocket Pharmaceuticals
RCKT
$380M
| $13.9M | 0.28% |
+870,000
| New | +$13.6M |
|
50
AN2 Therapeutics
ANTX
$182M
| $12.5M | 0.25% |
716,538
| – | – |
|
Similar funds
FT
GRQ
PCM
VA
QC
IC
NW
AAF
Deerfield Management's Q3 2022 Portfolio in Review
As of Q3 2022, Deerfield Management held 141 positions worth $5.02B, up 3.6% from $4.85B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Deerfield Management withdrew a net $2.02B in Q3 2022, closing 12 positions and reducing 22 holdings. Its most notable exit was Glaukos, an estimated $53.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 53% of assets, up from 51% a quarter earlier, followed by Financials.
Against the trend, Deerfield Management opened a new position in Biogen worth $88.1M.
- Deerfield Management's largest Q3 2022 buy was Biogen: 330,000 shares worth $88.1M.
- Deerfield Management added most to Revolution Medicines in Q3 2022, an estimated $44M increase.
- Deerfield Management's biggest Q3 2022 reduction was Viatris, cutting an estimated $98.4M.
- Deerfield Management fully exited Glaukos in Q3 2022, selling an estimated $53.6M.
- Deerfield Management's ten largest holdings make up 38% of its $5.02B portfolio in Q3 2022.
- Deerfield Management opened 17 new positions and closed 12 in Q3 2022.
- Deerfield Management's portfolio value rose 3.6% quarter-over-quarter to $5.02B.
Based on Deerfield Management's 13F filing for Q3 2022, filed 14 Nov 2022.